ICOS Announces Initiation of Overseas Phase 2 Trial With IC351
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 13, 1998--ICOS Corporation (NASDAQ:ICOS - news) announced today the initiation of a Phase 2 clinical trial with IC351 in patients with male erectile dysfunction (MED).
This randomized placebo-controlled, crossover study is being performed overseas.
The Phase 2 clinical trial includes patients with mild to moderate MED. The study is designed to assess the safety and physiological effects of IC351 in this patient population.
Approximately 20-30 million men in the United States are estimated to suffer from some degree of MED. This condition, sometimes referred to as impotence, can be a consequence of several factors, among them cardiovascular insufficiency.
IC351 is a selective PDE5 phosphodiesterase inhibitor that is thought to reinforce the normal physiological signals to increase blood flow. Such an increase in blood flow is an integral part of the erectile response. The Company's goal is to demonstrate that IC351 is a useful treatment for MED and cardiovascular disorders.
ICOS is discovering and developing new pharmaceuticals by seeking points of intervention in the inflammatory process that may lead to specific and efficacious drugs. ICOS' research and drug development programs involve both acute and chronic conditions such as ARDS, acute pancreatitis, asthma, hemorrhagic shock, male erectile dysfunction, multiple sclerosis, myocardial infarction, and psoriasis.
Another oral drug that is in Phase II. Apparently, the less you need a drug, the better the pills work. This is a Viagra "me-too" drug.
Zebra |
